Lyell Immunopharma News

HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

BenzingaFeb 29 15:21 ET

Lyell Immunopharma Analyst Ratings

BenzingaFeb 29 15:19 ET

HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $8

BenzingaNov 9, 2023 07:38 ET

Lyell Immunopharma Analyst Ratings

BenzingaNov 9, 2023 07:37 ET

Promising Financial and Clinical Prospects: A Comprehensive Buy Rating Analysis for Lyell Immunopharma

TipRanksNov 9, 2023 06:46 ET

JP Morgan Cuts Lyell to Neutral, Pending Data for Cell Therapy Platform

Seeking AlphaAug 28, 2023 17:41 ET

JP Morgan Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $5

BenzingaAug 28, 2023 04:48 ET

Lyell Immunopharma Analyst Ratings

BenzingaAug 28, 2023 04:47 ET

H.C. Wainwright Reaffirms Their Buy Rating on Lyell Immunopharma (LYEL)

TipRanksAug 9, 2023 06:35 ET

HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $9 Price Target

BenzingaMay 5, 2023 06:54 ET

Lyell Immunopharma (LYEL) Receives a Buy From H.C. Wainwright

TipRanksMay 5, 2023 06:37 ET

HC Wainwright Adjusts Price Target on Lyell Immunopharma to $9 From $11, Maintains Buy Rating

MT NewswiresMar 2, 2023 07:38 ET

Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $4 From $7, Maintains Equal Weight Rating

MT NewswiresJan 24, 2023 11:40 ET

Morgan Stanley Sticks to Its Hold Rating for Lyell Immunopharma (LYEL)

TipRanksJan 24, 2023 11:30 ET

Lyell Immunopharma Analyst Ratings

Benzinga Analyst RatingsJan 24, 2023 09:04 ET

Morgan Stanley Maintains Equal-Weight on Lyell Immunopharma, Lowers Price Target to $4

Benzinga Real-time NewsJan 24, 2023 09:04 ET

Lyell Immunopharma Analyst Ratings

Benzinga Analyst RatingsNov 14, 2022 06:22 ET

Morgan Stanley Downgrades Lyell Immunopharma to Equal-Weight, Lowers Price Target to $7

Benzinga Real-time NewsNov 14, 2022 06:22 ET

Lyell Immunopharma Analyst Ratings

Benzinga Analyst RatingsNov 11, 2022 13:27 ET

Lyell Immunopharma Analyst Ratings

Benzinga Analyst RatingsOct 17, 2022 06:23 ET